Is Vident International Equity Strategy ETF (VIDI) a Strong ETF Right Now?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 13 2024
0mins
Should l Buy JAZZ?
Source: NASDAQ.COM
Overview of Vident International Equity Strategy ETF (VIDI): Launched in 2013, VIDI is a smart beta ETF that aims to outperform the World ETFs segment by utilizing a principles-based selection strategy and balancing risk across developed and emerging markets, with an expense ratio of 0.61% and a 12-month dividend yield of 3.50%.
Comparison with Other ETFs: While VIDI has shown positive performance, investors may also consider lower-cost traditional market cap weighted ETFs like Vanguard Total International Stock ETF (VXUS) and Vanguard FTSE Developed Markets ETF (VEA), which have significantly lower expense ratios and larger asset bases.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy JAZZ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on JAZZ
Wall Street analysts forecast JAZZ stock price to rise
13 Analyst Rating
12 Buy
1 Hold
0 Sell
Strong Buy
Current: 185.010
Low
188.00
Averages
218.92
High
263.00
Current: 185.010
Low
188.00
Averages
218.92
High
263.00
About JAZZ
Jazz Pharmaceuticals plc is a global biopharmaceutical company. It is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. It has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
American Nutrition Association Partners with Jazz Pharmaceuticals to Promote Low Sodium Diets
- Joint Initiative: The American Nutrition Association (ANA) collaborates with Jazz Pharmaceuticals to launch an initiative aimed at providing evidence-based nutritional education for patients with narcolepsy or idiopathic hypersomnia, addressing cardiovascular and cardiometabolic risks.
- High Sodium Risks: Research indicates that patients with narcolepsy experience significantly higher rates of cardiovascular and cardiometabolic comorbidities, with excessive sodium intake being a critical modifiable risk factor for hypertension and cardiovascular disease, necessitating increased awareness through education.
- Patient Empowerment: This partnership will provide patients with credible, science-backed resources to understand the benefits and risks of sodium intake, enabling them to gain greater control over their health choices and improve their quality of life.
- Provider Support: Healthcare providers will receive evidence-based resources to facilitate meaningful discussions with patients about sodium reduction as a cornerstone of cardiovascular risk management, ultimately promoting better patient outcomes.
See More
American Nutrition Association Partners with Jazz Pharmaceuticals to Promote Low Sodium Diets
- Collaborative Initiative: The American Nutrition Association (ANA) has partnered with Jazz Pharmaceuticals to launch an initiative aimed at providing evidence-based nutritional education for patients with narcolepsy and idiopathic hypersomnia, emphasizing the importance of proactive sodium management in addressing cardiovascular and cardiometabolic risks.
- Cardiovascular Risks: Research indicates that individuals with narcolepsy experience significantly higher rates of cardiovascular and cardiometabolic comorbidities, with excessive sodium intake linked to hypertension and cardiovascular disease, contributing to approximately 700,000 deaths annually in the U.S., highlighting the urgent need for increased awareness.
- Patient Empowerment: This collaboration will provide patients with credible, science-backed resources to understand the risks and benefits of sodium intake, enabling them to make informed health choices, while healthcare providers will be better equipped to engage in meaningful discussions with patients about sodium reduction.
- Science and Education Integration: ANA's CEO, Corinne Bush, emphasized that nutrition science is a core value, and this partnership with Jazz Pharmaceuticals aims to translate scientific knowledge into actionable guidance for patients, ultimately improving health outcomes for those affected.
See More
Jazz Pharmaceuticals Unveils New Research Insights at AACR Annual Meeting
- New Drug Research Progress: Jazz Pharmaceuticals will present seven research findings at the 2026 American Association for Cancer Research Annual Meeting, including the application of Ziihera® (zanidatamab-hrii) in HER2-positive tumors, demonstrating significant efficacy in treating metastatic biliary tract cancer, thereby reinforcing its leadership in oncology.
- Clinical Trial Data: Data from the NeoZanHER trial will support the use of zanidatamab in early-stage HER2-positive breast cancer patients, which is expected to enhance the drug's clinical application in a broader range of HER2-expressing tumors, increasing the company's competitiveness in the oncology market.
- Innovative Research Initiatives: Jazz will also showcase studies on dordaviprone and JZP898, with the former showing potent cytotoxic effects in small cell lung cancer cell lines, while the latter demonstrates robust tumor microenvironment engagement in mouse models, indicating potential in tumor immunotherapy.
- Strategic Investments and Collaborations: The research findings not only reflect Jazz's ongoing investment in oncology drug development but also highlight the company's close collaboration with multiple partners, aiming to improve treatment options for patients through innovative therapies and further drive growth in the global biopharmaceutical market.
See More
Investors Shift Focus to Updated Quant Ratings Post Earnings
- Market Underperformance: The State Street Health Care Select Sector SPDR ETF (XLV) has lagged in the current market environment, retreating 3.00% year-to-date, which is notably worse than the S&P 500's 2.53% decline, indicating investor caution towards the healthcare sector.
- Quant Rating System: Seeking Alpha's quant system rates stocks on a scale from 1 to 5, with scores of 3.5 or above classified as bullish and 2.5 or below as bearish, providing a comprehensive assessment of companies across key factors such as valuation, growth, and profitability.
- Top-Rated Stocks: Among large-cap real estate companies, DaVita and Jazz Pharmaceuticals both received a quant rating of 4.79, classified as Strong Buy, highlighting their strong market performance and investment appeal.
- Bottom-Rated Stocks: CSL Limited and Daiichi Sankyo Company received quant ratings of 1.37 and 1.44, respectively, classified as Strong Sell, indicating significant pressure on these companies in the current market environment, warranting caution from investors.
See More
S&P 500 Futures Decline in Pre-Market Trading; Jazz Pharmaceuticals and Live Nation Entertainment at the Forefront
Market Opening: U.S. stock markets are set to open in two hours.
Jazz Pharmaceuticals Performance: Jazz Pharmaceuticals PLC (JAZZ) saw a 10.7% increase in pre-market trading.
Live Nation Entertainment Performance: Live Nation Entertainment Inc. (LYV) experienced an 8.9% rise in pre-market trading.
Overall Market Sentiment: The pre-market gains indicate positive sentiment among investors for these companies.
See More
Analysis of Growth Drivers in the Biliary Tract Cancer Market
- Market Size Growth: The biliary tract cancer market is projected to reach $1.1 billion in 2024, with the U.S. accounting for approximately 60% of this market, indicating a strong demand for new therapies in this leading region.
- Emerging Drug Launches: The introduction of new drugs such as Tinengotinib and Rilvegostomig is expected to further drive market growth, particularly in the areas of targeted therapies and immuno-oncology, enhancing treatment options for patients.
- Advancements in Diagnostic Technology: Improvements in imaging techniques like MRI, endoscopic ultrasound, and PET have enhanced the accuracy of biliary tract cancer diagnoses, enabling earlier detection and personalized treatment approaches, thereby improving patient outcomes.
- Market Dynamics in Treatment: By 2034, chemotherapy is expected to remain the primary revenue source for biliary tract cancer treatment, and the introduction of new therapies will alter the competitive landscape, fostering medical innovation and economic growth.
See More
American Nutrition Association Partners with Jazz Pharmaceuticals to Promote Low Sodium Diets
- Joint Initiative: The American Nutrition Association (ANA) collaborates with Jazz Pharmaceuticals to launch an initiative aimed at providing evidence-based nutritional education for patients with narcolepsy or idiopathic hypersomnia, addressing cardiovascular and cardiometabolic risks.
- High Sodium Risks: Research indicates that patients with narcolepsy experience significantly higher rates of cardiovascular and cardiometabolic comorbidities, with excessive sodium intake being a critical modifiable risk factor for hypertension and cardiovascular disease, necessitating increased awareness through education.
- Patient Empowerment: This partnership will provide patients with credible, science-backed resources to understand the benefits and risks of sodium intake, enabling them to gain greater control over their health choices and improve their quality of life.
- Provider Support: Healthcare providers will receive evidence-based resources to facilitate meaningful discussions with patients about sodium reduction as a cornerstone of cardiovascular risk management, ultimately promoting better patient outcomes.
See More
American Nutrition Association Partners with Jazz Pharmaceuticals to Promote Low Sodium Diets
- Collaborative Initiative: The American Nutrition Association (ANA) has partnered with Jazz Pharmaceuticals to launch an initiative aimed at providing evidence-based nutritional education for patients with narcolepsy and idiopathic hypersomnia, emphasizing the importance of proactive sodium management in addressing cardiovascular and cardiometabolic risks.
- Cardiovascular Risks: Research indicates that individuals with narcolepsy experience significantly higher rates of cardiovascular and cardiometabolic comorbidities, with excessive sodium intake linked to hypertension and cardiovascular disease, contributing to approximately 700,000 deaths annually in the U.S., highlighting the urgent need for increased awareness.
- Patient Empowerment: This collaboration will provide patients with credible, science-backed resources to understand the risks and benefits of sodium intake, enabling them to make informed health choices, while healthcare providers will be better equipped to engage in meaningful discussions with patients about sodium reduction.
- Science and Education Integration: ANA's CEO, Corinne Bush, emphasized that nutrition science is a core value, and this partnership with Jazz Pharmaceuticals aims to translate scientific knowledge into actionable guidance for patients, ultimately improving health outcomes for those affected.
See More
Jazz Pharmaceuticals Unveils New Research Insights at AACR Annual Meeting
- New Drug Research Progress: Jazz Pharmaceuticals will present seven research findings at the 2026 American Association for Cancer Research Annual Meeting, including the application of Ziihera® (zanidatamab-hrii) in HER2-positive tumors, demonstrating significant efficacy in treating metastatic biliary tract cancer, thereby reinforcing its leadership in oncology.
- Clinical Trial Data: Data from the NeoZanHER trial will support the use of zanidatamab in early-stage HER2-positive breast cancer patients, which is expected to enhance the drug's clinical application in a broader range of HER2-expressing tumors, increasing the company's competitiveness in the oncology market.
- Innovative Research Initiatives: Jazz will also showcase studies on dordaviprone and JZP898, with the former showing potent cytotoxic effects in small cell lung cancer cell lines, while the latter demonstrates robust tumor microenvironment engagement in mouse models, indicating potential in tumor immunotherapy.
- Strategic Investments and Collaborations: The research findings not only reflect Jazz's ongoing investment in oncology drug development but also highlight the company's close collaboration with multiple partners, aiming to improve treatment options for patients through innovative therapies and further drive growth in the global biopharmaceutical market.
See More
Investors Shift Focus to Updated Quant Ratings Post Earnings
- Market Underperformance: The State Street Health Care Select Sector SPDR ETF (XLV) has lagged in the current market environment, retreating 3.00% year-to-date, which is notably worse than the S&P 500's 2.53% decline, indicating investor caution towards the healthcare sector.
- Quant Rating System: Seeking Alpha's quant system rates stocks on a scale from 1 to 5, with scores of 3.5 or above classified as bullish and 2.5 or below as bearish, providing a comprehensive assessment of companies across key factors such as valuation, growth, and profitability.
- Top-Rated Stocks: Among large-cap real estate companies, DaVita and Jazz Pharmaceuticals both received a quant rating of 4.79, classified as Strong Buy, highlighting their strong market performance and investment appeal.
- Bottom-Rated Stocks: CSL Limited and Daiichi Sankyo Company received quant ratings of 1.37 and 1.44, respectively, classified as Strong Sell, indicating significant pressure on these companies in the current market environment, warranting caution from investors.
See More
S&P 500 Futures Decline in Pre-Market Trading; Jazz Pharmaceuticals and Live Nation Entertainment at the Forefront
Market Opening: U.S. stock markets are set to open in two hours.
Jazz Pharmaceuticals Performance: Jazz Pharmaceuticals PLC (JAZZ) saw a 10.7% increase in pre-market trading.
Live Nation Entertainment Performance: Live Nation Entertainment Inc. (LYV) experienced an 8.9% rise in pre-market trading.
Overall Market Sentiment: The pre-market gains indicate positive sentiment among investors for these companies.
See More
Analysis of Growth Drivers in the Biliary Tract Cancer Market
- Market Size Growth: The biliary tract cancer market is projected to reach $1.1 billion in 2024, with the U.S. accounting for approximately 60% of this market, indicating a strong demand for new therapies in this leading region.
- Emerging Drug Launches: The introduction of new drugs such as Tinengotinib and Rilvegostomig is expected to further drive market growth, particularly in the areas of targeted therapies and immuno-oncology, enhancing treatment options for patients.
- Advancements in Diagnostic Technology: Improvements in imaging techniques like MRI, endoscopic ultrasound, and PET have enhanced the accuracy of biliary tract cancer diagnoses, enabling earlier detection and personalized treatment approaches, thereby improving patient outcomes.
- Market Dynamics in Treatment: By 2034, chemotherapy is expected to remain the primary revenue source for biliary tract cancer treatment, and the introduction of new therapies will alter the competitive landscape, fostering medical innovation and economic growth.
See More
